Results 111 to 120 of about 6,343 (174)
Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis. [PDF]
ACG Case Rep JSrivoleti P, Dhillon N, Boneschansker L.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hospital Pharmacy, 2007
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Mesalamine-Associated Thrombocytopenia
American Journal of Gastroenterology, 1999We describe a case of a 25-yr-old woman with ulcerative colitis who developed marked thrombocytopenia during treatment and upon rechallenge with oral mesalamine. In contrast to its parent drug, sulfasalazine, which has often been reported to cause serious blood disorders, particularly agranulocytosis, mesalamine has rately been implicated as a cause of
R J, Farrell +3 more
openaire +3 more sources